What is Nabriva Therapeutics?
Founded in 2006 and headquartered in Dublin, Ireland, Nabriva Therapeutics is a biopharmaceutical firm dedicated to the development and commercialization of innovative anti-infective agents designed to combat serious infections. The company's strategic focus on addressing critical unmet medical needs in infectious diseases positions it within a vital segment of the healthcare industry. Its commitment to advancing novel therapies highlights its role in the ongoing fight against antimicrobial resistance.
How much funding has Nabriva Therapeutics raised?
Nabriva Therapeutics has raised a total of $92.3M across 1 funding round:
Stock Offering
$92.3M
Stock Issuance/Offering (2015): $92.3M, investors not publicly disclosed
What's next for Nabriva Therapeutics?
The recent major strategic investment signals a pivotal phase for Nabriva Therapeutics, likely enabling the acceleration of its drug development pipeline, clinical trials, and potential commercialization efforts. This enterprise-level capital infusion is expected to bolster its research and development capabilities, allowing the company to further its mission of bringing new anti-infective treatments to market. The company's trajectory suggests a strong emphasis on scaling operations and expanding its therapeutic offerings to address global health challenges.
See full Nabriva Therapeutics company page
